Table 2.
Characteristics of patients enrolled in studies selected for the final analysis
| Author, year | Main treatment | Inclusion criteria | Numbers of individuals randomized | Number available for the final analysis | Male, % | Age, yrs | BMI, Kg/m2 | Basal FEV1, % | |
|---|---|---|---|---|---|---|---|---|---|
| Man WDC, 2004 | Salmeterol 50 μg bid | FEV1 change post bd < 10% and 200 ml | 20 | 16 | 63 | 68 (7.6) | – | 31.1 (3.9) | |
| O’Donnell DE, 2004 | Salmeterol 50 μg bid | FEV1 ≤ 70%, FRC ≥ 120%, BDI ≤ 6 | 23 | 23 | 65 | 64 (2.0) | 26.1 (0.8) | 42 (−) | |
| Neder JA, 2007 | Formoterol 12 μg bid | FEV1/FVC ≤ 60%, FEV1 < 60% and change after bd < 12% | 21 | 18 | 67 | 42–75 (range) | 24.8 (5.1) | 38.8 (11.7) | |
| Beeh KM, 2011 | Indacaterol 300 μg od | 40–80 yrs., 80% ≥ FEV1 ≥ 40%, FRC ≥ 120% | 27 | 24 | 67 | 61.3 (7.2) | 25.6 (3.4) | 51.5 (11.4) | |
| O’Donnell DE, 2011 | Indacaterol 300 μg od | ≥40 yrs., 80% ≥ FEV1 ≥ 30% | 90 | 74 | 70 | 62.8 (8.2) | 27.5 (4.1) | 61 (12.4) | |
| Maltais F, 2016 | Study 1222.37 | Olodaterol 5, 10 μg | 40–75 yrs., FEV1 < 80% | 151 | 140 | 77 | 60.6 (7.7) | – | 48.5 (14.5) |
| Study 1222.38 | 157 | 141 | 74 | 60.6 (7.7) | – | 51.6 (14.2) | |||
| O’Donnell DE, 2004 | Tiotropium 18 μg od | 40–70 yrs., FEV1 ≤ 65%, FRC ≥ 120% | 198 | 187 | 74 | 60.5 (−) | 26.5 (4.8) | 44 (13.0) | |
| Casaburi R, 2005 | Tiotropium 18 μg od | ≥40 yrs., FEV1 ≤ 60% | 108 | 91 | 57 | 66.6 (7.9) | 25.9 (5.2) | 34.4 (12.4) | |
| Maltais F, 2005 | Tiotropium 18 μg od | 40–75 yrs., FEV1 ≤ 65%, FRC ≥ 120% | 261 | 241 | 72 | 62.5 (7.4) | – | 43.1 (12.7) | |
| Travers J, 2007 | Tiotropium 18 μg od | FEV1 ≤ 65%, FRC ≥ 120%, BDI ≤ 6 | – | 18 | 72 | 60 (9.0) | 26.8 (5.4) | 40 (−) | |
| Maltais F, 2011 | Aclidinium 200 μg od | ≥40 yrs., 80% ≥ FEV1 ≥ 30%, FRC ≥ 120%, BDI ≤ 7 | 181 | 159 | 52 | 64.8 (−) | 26.4 (−) | 50 (−) | |
| Beeh KM, 2012 | Glycopyrronium 50 μg od | ≥40 yrs., 80% ≥ FEV1 ≥ 40% | 108 | 95 | 58 | 60.5 (8.6) | 26.6 (4.0) | 57.1 (8.5) | |
| Cooper CB, 2013 | Tiotropium 18 μg od | ≥40 yrs., FEV1 ≤ 65%, mMRC≥2 | 519 | 464 | 77 | 65 (−) | 26.4 (−) | 44 (12.0) | |
| Beeh KM, 2014 | Aclidinium 400 μg bid | ≥40 yrs., 80% ≥ FEV1 ≥ 30%, FRC ≥ 120% | 112 | 106 | 68 | 60.3 (8.1) | – | 56.7 (11.6) | |
| Casaburi R, 2014 | Tiotropium 18 μg od | ≥40 yrs., FEV1 ≥ 50%, 35 ≥ BMI ≥ 18 Kg/m2, BDI ≤ 9 | 126 | 111 | 52 | 61.2 (8.8) | 27.8 (3.9) | 70 (17.0) | |
| Bedard M-E, 2012 | Tiotropium 18 μg od | ≥50 yrs., FEV1 < 70% | 36 | 34 | 68 | 65 (7) | 28 (4) | 54 (12) | |
| Beeh KM, 2014 | Indacaterol/Glycopyrronium 110/50 μg od | ≥40 yrs., 70% ≥ FEV1 ≥ 40% | 85 | 73 | 63 | 62.1 (8.1) | – | 56 (8.9) | |
| Maltais F, 2014 | Study 417 | Umeclidinium/vilanterol 125/25, 62,5/25 μg | ≥40 yrs., 70% ≥ FEV1 ≥ 35%, FRC ≥ 120%, mMRC≥2 | 349 | 348 | 56 | 61.6 (8.3) | – | 51.3 (9.7) |
| Study 418 | 308 | 307 | 55 | 62.6 (7.9) | – | 51.3 (10.0) | |||
| O’Donnell, 2017 | Mor 1 | Olodaterol/Tiotropium 2,5/5, 5/5 μg | 40–75 yrs., 80% ≥ FEV1 ≥ 30% | 295 | 227 | 72 | 62.2 (7.5) | 27.3 (5.3) | 52.6 (13.9) |
| Mor 2 | 291 | 224 | 70 | 61.2 (7.9) | 26.7 (4.6) | 52.0 (13.4) | |||
| O’Donnell DE, 2006 | Salmeterol 50 μg/Fluticasone 250 μg bid | ≥40 yrs., FEV1 < 70%, FRC ≥ 120%, BDI < 7, ≥20 W at CPET | 123 | 117 | 70 | 64 (−) | 25.9 (−) | 41 (−) | |
| Worth H, 2010 | Budesonide/formoterol 320/9 μg bid | ≥exacerbation last 1 yr., FEV1 ≤ 50%, FRC > 120% | 111 | 91 | 76 | 63.7 (−) | 25.7 (−) | 37 (8.4) | |
| Guenette JA, 2013 | Fluticasone 250/Salmeterol 50 μg bid | ≥40 yrs., FEV1 > 60% | 18 | 15 | 40 | 64 (10.0) | 29.5 (6.4) | 86 (15.0) | |
Od Once daily, bid Twice daily, bd Bronchodilation, Mor MORACTO study